# A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia

Study · id `cardio:ct-nct07421232` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07421232](<https://clinicaltrials.gov/study/NCT07421232>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07421232

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 156 participants.

## Technical summary

Registry record NCT07421232. Randomized; single masking; primary purpose treatment. Start 2024-12-03 (actual); primary completion 2025-08-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 156 participants (enrolled count; ClinicalTrials.gov record NCT07421232, source copy `cardio:ctgov-nct07421232-2026-02-19`, retrieved 2026-10-31)
- Started: 2024-12-03 (actual) (ClinicalTrials.gov record NCT07421232, source copy `cardio:ctgov-nct07421232-2026-02-19`, retrieved 2026-10-31)
- Primary completion: 2025-08-30 (actual) (ClinicalTrials.gov record NCT07421232, source copy `cardio:ctgov-nct07421232-2026-02-19`, retrieved 2026-10-31)
- Completion: 2026-02-12 (actual) (ClinicalTrials.gov record NCT07421232, source copy `cardio:ctgov-nct07421232-2026-02-19`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07421232, source copy `cardio:ctgov-nct07421232-2026-02-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07421232-2026-02-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
- Condition: Hypercholesterolemia and Mixed Hyperlipidemia
- Intervention (Drug): SYH2053/placebo injection
- Intervention (Drug): Inclisiran (Leqvio®) 300mg
- Lead sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Inclisiran (Leqvio) (`cardio:leqvio`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Inclisiran (`cardio:inclisiran`)
- Registry lists this organization as the lead sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (`cardio:org-cspc-zhongnuo-pharmaceutical-shijiazhuang-co-ltd`)

## Provenance

Content hash: 8e8db29e8bf35f30aa10843a1b4c33b9230f552e33e695b7593766555bbffe32
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
